Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) – Analysts at Cantor Fitzgerald issued their FY2024 EPS estimates for Regeneron Pharmaceuticals in a research note issued to investors on Tuesday, July 11th. Cantor Fitzgerald analyst O. Brayer expects that the biopharmaceutical company will post earnings of $33.17 per share for the year. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $33.63 per share.
Several other analysts also recently commented on REGN. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their target price for the stock from $953.00 to $720.00 in a research report on Wednesday, June 28th. EF Hutton Acquisition Co. I upped their price objective on shares of Regeneron Pharmaceuticals from $853.00 to $862.00 and gave the stock a “buy” rating in a report on Thursday, March 23rd. Morgan Stanley upped their price objective on shares of Regeneron Pharmaceuticals from $880.00 to $927.00 in a report on Friday, May 5th. Erste Group Bank reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 28th. Finally, SVB Leerink raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, March 27th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $874.00.
Regeneron Pharmaceuticals Stock Performance
REGN stock opened at $720.98 on Friday. The company has a quick ratio of 4.67, a current ratio of 5.45 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $79.10 billion, a price-to-earnings ratio of 19.59, a P/E/G ratio of 2.25 and a beta of 0.22. Regeneron Pharmaceuticals has a 12 month low of $563.82 and a 12 month high of $837.55. The firm has a 50 day moving average of $742.78 and a two-hundred day moving average of $757.62.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last posted its earnings results on Thursday, May 4th. The biopharmaceutical company reported $8.44 EPS for the quarter, topping the consensus estimate of $7.71 by $0.73. The company had revenue of $3.16 billion during the quarter, compared to the consensus estimate of $2.92 billion. Regeneron Pharmaceuticals had a net margin of 33.81% and a return on equity of 20.41%.
Institutional Investors Weigh In On Regeneron Pharmaceuticals
A number of hedge funds have recently made changes to their positions in the company. BlackRock Inc. increased its position in shares of Regeneron Pharmaceuticals by 2.7% during the 1st quarter. BlackRock Inc. now owns 9,418,300 shares of the biopharmaceutical company’s stock worth $7,738,735,000 after purchasing an additional 251,483 shares in the last quarter. EP Wealth Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at about $434,000. Dodge & Cox increased its position in Regeneron Pharmaceuticals by 7.3% in the 1st quarter. Dodge & Cox now owns 2,384,701 shares of the biopharmaceutical company’s stock valued at $1,959,437,000 after acquiring an additional 161,642 shares in the last quarter. Geode Capital Management LLC increased its position in Regeneron Pharmaceuticals by 0.5% in the 1st quarter. Geode Capital Management LLC now owns 2,217,993 shares of the biopharmaceutical company’s stock valued at $1,818,766,000 after acquiring an additional 10,003 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in Regeneron Pharmaceuticals by 26.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,178,232 shares of the biopharmaceutical company’s stock valued at $1,789,789,000 after acquiring an additional 454,510 shares in the last quarter. Institutional investors and hedge funds own 89.21% of the company’s stock.
Insider Activity
In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $735.42, for a total value of $73,542.00. Following the completion of the transaction, the director now owns 18,847 shares in the company, valued at approximately $13,860,460.74. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $735.42, for a total transaction of $73,542.00. Following the completion of the sale, the director now owns 18,847 shares in the company, valued at approximately $13,860,460.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael S. Brown sold 3,070 shares of the stock in a transaction dated Friday, April 21st. The stock was sold at an average price of $798.42, for a total transaction of $2,451,149.40. Following the sale, the director now owns 1,247 shares of the company’s stock, valued at approximately $995,629.74. The disclosure for this sale can be found here. In the last 90 days, insiders sold 3,770 shares of company stock worth $2,957,902. 8.83% of the stock is currently owned by corporate insiders.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Regeneron Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Regeneron Pharmaceuticals wasn’t on the list.
While Regeneron Pharmaceuticals currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Wondering when you’ll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
